Metformin: a new option in cancer treatment

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Metformin is a first-line antidiabetic medication for type 2 diabetes.
• Emerging evidence suggests metformin may lower cancer incidence and mortality in diabetic individuals.
• Metformin influences cellular energy sensing pathways, including AMPK and mTOR.

Purpose of the Study:

• To review preclinical data and clinical trial findings on metformin's anticancer effects.
• To explore metformin's potential role in managing breast and prostate cancers.

Main Methods:

• Summary of preclinical studies investigating metformin's impact on cancer cell lines.
• Analysis of clinical trial data assessing metformin's efficacy in cancer patients.
• Focus on the molecular mechanisms involving AMPK and mTOR pathways.

Main Results:

• Preclinical data indicate metformin inhibits tumor cell growth via mTOR pathway suppression.
• Observed decrease in phosphorylation of key proteins like S6K, rpS6, and 4E-BP1.
• Clinical trials are ongoing to validate these findings in human subjects.

Conclusions:

• Metformin's activation of AMPK and inhibition of mTOR presents a promising avenue for cancer therapy.
• Further clinical research is essential to establish metformin's definitive role in cancer treatment, particularly for breast and prostate cancers.